Skip to main content
Erschienen in: Annals of Hematology 5/2021

13.01.2021 | Letter to the Editor

Venetoclax-induced panniculitis in an acute myeloid leukemia patient

verfasst von: Po-Wei Liao, Ren Ching Wang, Tsung-Chih Chen, Chieh-Lin Jerry Teng

Erschienen in: Annals of Hematology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137–2145. https://doi.org/10.1182/blood.2020004856CrossRefPubMedPubMedCentral Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137–2145. https://​doi.​org/​10.​1182/​blood.​2020004856CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629. https://doi.org/10.1056/NEJMoa2012971CrossRefPubMed DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629. https://​doi.​org/​10.​1056/​NEJMoa2012971CrossRefPubMed
3.
Zurück zum Zitat Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF (2018) Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res 24(18):4371–4379. https://doi.org/10.1158/1078-0432.CCR-17-3761CrossRefPubMed Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF (2018) Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res 24(18):4371–4379. https://​doi.​org/​10.​1158/​1078-0432.​CCR-17-3761CrossRefPubMed
4.
Zurück zum Zitat DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216–228. https://doi.org/10.1016/S1470-2045(18)30010-XCrossRefPubMed DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216–228. https://​doi.​org/​10.​1016/​S1470-2045(18)30010-XCrossRefPubMed
5.
Zurück zum Zitat Michonneau D, Petrella T, Ortonne N, Ingen-Housz-Oro S, Franck N, Barete S, Battistella M, Beylot-Barry M, Vergier B, Maynadie M, Bodemer C, Hermine O, Bagot M, Brousse N, Fraitag S (2017) Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol 97(3):358–364. https://doi.org/10.2340/00015555-2543CrossRefPubMed Michonneau D, Petrella T, Ortonne N, Ingen-Housz-Oro S, Franck N, Barete S, Battistella M, Beylot-Barry M, Vergier B, Maynadie M, Bodemer C, Hermine O, Bagot M, Brousse N, Fraitag S (2017) Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol 97(3):358–364. https://​doi.​org/​10.​2340/​00015555-2543CrossRefPubMed
6.
Zurück zum Zitat Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, Lasater EA, Shi Y, Dave N, Riehm JJ, Robinson VA, Do AD, Li Y, Orr CJ, Sampath D, Raval A, Merchant M, Bhathena A, Salem AH, Hamel KM, Leverson JD, Donawho C, Pappano WN, Uziel T (2020) Venetoclax increases intra-tumoral effector T cells and anti-tumor efficacy in combination with immune checkpoint blockade. Cancer Discov CD-19-0759. https://doi.org/10.1158/2159-8290.CD-19-0759 Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, Lasater EA, Shi Y, Dave N, Riehm JJ, Robinson VA, Do AD, Li Y, Orr CJ, Sampath D, Raval A, Merchant M, Bhathena A, Salem AH, Hamel KM, Leverson JD, Donawho C, Pappano WN, Uziel T (2020) Venetoclax increases intra-tumoral effector T cells and anti-tumor efficacy in combination with immune checkpoint blockade. Cancer Discov CD-19-0759. https://​doi.​org/​10.​1158/​2159-8290.​CD-19-0759
Metadaten
Titel
Venetoclax-induced panniculitis in an acute myeloid leukemia patient
verfasst von
Po-Wei Liao
Ren Ching Wang
Tsung-Chih Chen
Chieh-Lin Jerry Teng
Publikationsdatum
13.01.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 5/2021
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-04372-0

Weitere Artikel der Ausgabe 5/2021

Annals of Hematology 5/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.